Posts by: Joana Carvalho

News

CSA Medical‘s RejuvenAir System received the designation of Breakthrough Device by the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic obstructive pulmonary disease (COPD). The ... Read more

April 9, 2019

Circassia Adding Cardiovascular Safety Data on Tudorza Label for COPD Patients

News

The U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application for the addition of new clinical data on on the label of Tudorza (aclidinium bromide), ... Read more

October 19, 2018October 19, 2018

FDA Approves New Label for Stiolto Respimat Showing Efficacy Against COPD Flare-ups

News

The U.S. Food and Drug Administration (FDA) approved a new label for Stiolto Respimat (a combination therapy of tiotropium bromide and olodaterol) based on data from clinical trials showing ... Read more

August 7, 2018August 7, 2018

Hospitalized COPD Patients with AFib More Likely to Develop Complications, Study Reports

News

Hospitalized patients with chronic obstructive pulmonary disease (COPD) who also suffer from atrial fibrillation (AFib), a condition where the heart beats faster, have a greater risk of developing liver ... Read more

Posts by: Joana Carvalho

Joana Carvalho

CSA Medical’s RejuvenAir System Gets FDA Breakthrough Device Designation

Circassia Adding Cardiovascular Safety Data on Tudorza Label for COPD Patients

FDA Approves New Label for Stiolto Respimat Showing Efficacy Against COPD Flare-ups

Hospitalized COPD Patients with AFib More Likely to Develop Complications, Study Reports

Pin It on Pinterest